2023 ESMO express: research on changing clinical practice for prostate cancer

VernacularTitle:2023 ESMO研究速递：改变未来前列腺癌临床实践的研究
Author: Bo DAI ¹ ; Shanshan WANG ; Dingwei YE
Author Information

1. 复旦大学附属肿瘤医院泌尿外科　复旦大学上海医学院肿瘤学系，上海　200032
Keywords: Prostate cancer; Research progress; Androgen receptor inhibitor
From: Chinese Journal of Urology 2023;44(12):885-888
CountryChina
Language:Chinese
Abstract: The 2023 European Society for Medical Oncology (ESMO) was held recently. In this conference, numbers of cutting-edge studies were discussed and published including advances in diagnosis and treatment, especially in prostate cancer. Studies that may influence clinical treatment decisions were summarized in this article, including timing of radiotherapy after radical prostatectomy, Enzalutamide in biochemically recurrent prostate cancer, predictive factors of novel hormonal therapies in metastatic hormone-sensitive prostate cancer, and the value of osteoprotective agent. The purpose of this article was to help clinicians make better clinical decisions.